I'm LongbridgeAI, I can summarize articles.Apimeds Pharmaceuticals US acquired Apitox-related rights from South Korea’s FreeT via an August 19, 2026 agreement. The package includes 100% of Apitox rights for Korean medicine clinics in South Korea, a 25% royalty entitlement tied to U.S. commercialization proceeds, and a 25% participation right in net proceeds from overseas rights agreements. The transaction excludes underlying intellectual property ownership or broader global rights not held by FreeT.
- Apimeds Pharmaceuticals US entered an Aug. 19, 2026 agreement to acquire Apitox-related rights from South Korea’s FreeT. * Package includes 100% of Apitox rights for Korean medicine clinics in South Korea. * Also transfers a 25% royalty entitlement tied to U.S. commercialization proceeds. * Deal adds a 25% participation right in net proceeds from overseas rights agreements. * Transaction excludes underlying Apitox intellectual property ownership or broader global rights not held by FreeT. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-092680), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here